The design and rationale of the Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia (ACCURATE) study.
Acute coronary syndrome
Coronary artery disease
Familial hypercholesterolemia
Genetics
Lipids
Lipoproteins
Journal
American heart journal plus : cardiology research and practice
ISSN: 2666-6022
Titre abrégé: Am Heart J Plus
Pays: United States
ID NLM: 101779333
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
19
11
2021
revised:
12
01
2022
accepted:
18
01
2022
medline:
4
2
2022
pubmed:
4
2
2022
entrez:
1
4
2024
Statut:
epublish
Résumé
Familial hypercholesterolemia (FH) is an inherited condition characterized by elevated low-density lipoprotein cholesterol (LDL-C) levels and premature atherosclerotic cardiovascular disease (ASCVD). Despite being the most common inherited cardiovascular disorder, it is still highly underdiagnosed and undertreated worldwide. We designed the Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia (ACCURATE) study to test the hypothesis that opportunistic genetic testing for FH among patients hospitalized for acute coronary syndrome (ACS) will increase the diagnosis of FH and improve patient outcomes. ACCURATE is a non-randomized, controlled trial of patients <60 years old admitted to an acute cardiac unit with ACS and elevated LDL-C levels. The first cohort will consist of a control group of patients presenting with ACS who will be treated according to usual standard-of-care. The second cohort will consist of patients presenting with ACS in whom research-based genetic testing for FH will be performed during hospitalization and the results returned to the treating physicians. The primary endpoint will be the number of patients with a new diagnosis of FH. The secondary endpoints will be the proportion of patients who undergo intensification of lipid-lowering therapy, the lowest LDL-C level achieved, and the proportion of patients reaching guideline recommended lipid targets in the 12 months after the index ACS. To our knowledge, ACCURATE represents the first clinical trial of genetic testing for FH in the acute cardiac care setting and is expected to help identify optimal approaches to increase the diagnosis and treatment of FH.
Identifiants
pubmed: 38560068
doi: 10.1016/j.ahjo.2022.100097
pii: S2666-6022(22)00014-3
pmc: PMC10978219
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100097Informations de copyright
© 2022 The Authors. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.